27 Jan, 2012
Ranbaxy loses over 6% after US files 'ground-breaking' consent decree in court
Stock prices of Ranbaxy dropped nearly 7% on Friday after a consent decree was filed in a United States court that demands the drug company to make fundamental changes at its plants in the US and India.
Source: BloombergUTV.com
Company:
RANBAXY LAB.